Session Description: S-Adenosyl-L-methionine (SAMe), a metabolite present in all living cells, plays a central role in cellular biochemistry as a precursor to methylation, aminopropylation, and transsulfuration pathways. As such, SAMe has been studied extensively since its chemical structure was first described in 1952. Decades of research on the biochemical and molecular roles of SAMe in cellular metabolism have provided an extensive foundation for its use in clinical studies. Studies have shown that SAMe, when given in high pharmacologic doses, is absorbed and is utilized by being incorporated into the endogenous cellular pathways inherent in all cells. In disease states in which SAMe concentrations are reduced (either as a result of genetic defects, drug effects, or the disease process itself), there is a rational basis for administering SAMe to restore methyl-group metabolism. A sufficient number of clinical trials have supported the use of SAMe in disorders including depression, dementia, vacuolar myelopathy, and liver disease. This presentation will provided an overview of the biochemical, molecular, and therapeutic effects of this pleiotrophic molecule.
- Participants will be able to discuss the importance of methylation in the cell metabolism and how it applies to optimal health.
- Participants will be able to discuss the biochemical mechanisms of methyl-group deficiency that are involved in neuropsychiatric disorders and other disorders.
- Participants will be able to identify clinical applications and the potential of S-adenosymethionine and other methyl group donor therapies.
About The Speaker:
Teodoro Bottiglieri Ph.D. obtained his masters (MSc) and doctorate (Ph.D.) at the University of London, United Kingdom on the role of folate in neurological and psychiatric diseases. He joined the Institute of Metabolic Disease (IMD), Baylor Research Institute in October 1991, and is currently the Program Director of the Center of Metabolomics at Baylor Scott & White Research Institute. Dr. Bottiglieri’s research program focuses on identifying biomarkers that will aid in diagnosing and monitoring disease progression and outcome in common and rare diseases. He has a specific interest in understanding the role of folate, vitamin B12 and methylation in the central nervous system. The research conducted in Dr. Bottiglieri’s laboratory has application to many disease states, including diagnosis of rare in-born errors of metabolism, Alzheimer’s disease, Parkinson’s disease, depression and vascular disease. Dr. Bottiglieri research over the last 25 years involves both preclinical (experimental models) and clinical studies on the metabolism and use of folate and related methyl-group donors in neurodegenerative and vascular disorders. He has over 194 publications in peer reviewed journals and co-authored several textbooks, “S-adenosylmethionine (SAMe): Stop depression Now” Penguin Putman 1999, 2000; and “Homocysteine and related Vitamins in Neuropsychiatry” Springer Verlag, 2003. His research is supported by funding from the National Institute of Health (NIH), independent foundations and the Pharmaceutical industry. He Lectures frequently at national and international meetings and is active in a number of professional organizations including the Society of Neuroscience, the American society of Neurochemistry, American Academy of Neurology and the American Heart Association.